Chinese Position Paper on Biologic Therapy for Allergic Rhinitis - PubMed
4 hours ago
- #allergic rhinitis
- #biologic therapy
- #China
- Allergic rhinitis (AR) is a common nasal disorder with significant public health challenges.
- Current treatments often fail to control symptoms adequately in many patients.
- Biologic therapies targeting type 2 inflammatory pathways are used for uncontrolled AR symptoms.
- Recent approval of novel agents like stapokibart has accelerated clinical research in AR.
- Evidence for biologic therapy in perennial allergic rhinitis (PAR) is currently limited.
- A multidisciplinary expert panel provided recommendations to standardize biologic use in AR.
- The paper evaluates efficacy and safety of biologic agents, incorporating international and regional data.
- Recommendations focus on biologic therapy for uncontrolled seasonal allergic rhinitis (SAR).